BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 32217763)

  • 41. Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein.
    Pan Z; Di S; Shi B; Jiang H; Shi Z; Liu Y; Wang Y; Luo H; Yu M; Wu X; Li Z
    Cancer Immunol Immunother; 2018 Oct; 67(10):1621-1634. PubMed ID: 30078052
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radiolabeled Monoclonal Antibody Against Colony-Stimulating Factor 1 Receptor Specifically Distributes to the Spleen and Liver in Immunocompetent Mice.
    Waaijer SJH; Suurs FV; Hau CS; Vrijland K; de Visser KE; de Groot DJA; de Vries EGE; Lub-de Hooge MN; Schröder CP
    Front Oncol; 2021; 11():786191. PubMed ID: 34976826
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination of T cell-redirecting bispecific antibody ERY974 and chemotherapy reciprocally enhances efficacy against non-inflamed tumours.
    Sano Y; Azuma Y; Tsunenari T; Kayukawa Y; Shinozuka J; Fujii E; Amano J; Nishito Y; Maruyama T; Kinoshita Y; Sakamoto Y; Yoshida A; Miyazaki Y; Sato Y; Teramoto-Seida C; Ishiguro T; Tanaka T; Kitazawa T; Endo M
    Nat Commun; 2022 Sep; 13(1):5265. PubMed ID: 36071036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In Vitro and In Vivo Characterization of
    Allen KJH; Jiao R; Li J; Beckford-Vera DR; Dadachova E
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235126
    [No Abstract]   [Full Text] [Related]  

  • 45. MicroPET imaging of integrin αvβ3 expressing tumors using 89Zr-RGD peptides.
    Jacobson O; Zhu L; Niu G; Weiss ID; Szajek LP; Ma Y; Sun X; Yan Y; Kiesewetter DO; Liu S; Chen X
    Mol Imaging Biol; 2011 Dec; 13(6):1224-33. PubMed ID: 21161690
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
    Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
    Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Site-specifically labeled
    Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
    Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice.
    Chen X; Chen Y; Liang R; Xiang L; Li J; Zhu Y; He H; Huang L; Zuo D; Li W; Liang X; Dong S; Hu S; Ho M; Feng M
    Mol Cancer Ther; 2022 Jan; 21(1):149-158. PubMed ID: 34725191
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
    Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
    Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies.
    Verel I; Visser GW; Boellaard R; Stigter-van Walsum M; Snow GB; van Dongen GA
    J Nucl Med; 2003 Aug; 44(8):1271-81. PubMed ID: 12902418
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-in-Humans Imaging with
    Pandit-Taskar N; Postow MA; Hellmann MD; Harding JJ; Barker CA; O'Donoghue JA; Ziolkowska M; Ruan S; Lyashchenko SK; Tsai F; Farwell M; Mitchell TC; Korn R; Le W; Lewis JS; Weber WA; Behera D; Wilson I; Gordon M; Wu AM; Wolchok JD
    J Nucl Med; 2020 Apr; 61(4):512-519. PubMed ID: 31586002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of a novel monoclonal antibody against tumor-associated MUC1 for diagnosis and prognosis of breast cancer.
    Stergiou N; Nagel J; Pektor S; Heimes AS; Jäkel J; Brenner W; Schmidt M; Miederer M; Kunz H; Roesch F; Schmitt E
    Int J Med Sci; 2019; 16(9):1188-1198. PubMed ID: 31588183
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics and Biodistribution of
    Ghosh S; Fletcher NL; Huda P; Houston ZH; Howard CB; Lund ME; Lu Y; Campbell DH; Walsh BJ; Thurecht KJ
    Mol Pharm; 2023 Mar; 20(3):1549-1563. PubMed ID: 36602058
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models.
    Sandker GGW; Middelburg J; Wilbrink E; Molkenboer-Kuenen J; Aarntzen E; van Hall T; Heskamp S
    J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37899133
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing
    Cho H; Al-Saden N; Lam H; Möbus J; Reilly RM; Winnik MA
    Nucl Med Biol; 2020; 84-85():11-19. PubMed ID: 31931305
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiolabelling and preclinical characterization of
    Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.
    Lund ME; Howard CB; Thurecht KJ; Campbell DH; Mahler SM; Walsh BJ
    BMC Cancer; 2020 Dec; 20(1):1214. PubMed ID: 33302918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.